Pharma Mar, S.A. (PHMMF)
Pharma Mar, S.A. is a biopharmaceutical firm dedicated to the discovery, development, manufacturing, and commercialization of bioactive compounds derived from marine organisms, primarily targeting oncology applications. Its products and research initiatives reach across key markets including Spain, Italy, Germany, Ireland, the broader European Union, the United States, and other international territories. The company's operations are structured across three distinct segments: Oncology, Diagnostics, and RNA Interference. Within its oncology portfolio, Pharma Mar markets Yondelis®, prescribed for soft tissue sarcomas and ovarian cancer, alongside Aplidin® for multiple myeloma, and Zepzelca®, which addresses small cell lung cancer. Additionally, the company has PM14, currently undergoing Phase II clinical trials for the treatment of various solid tumors. Beyond oncology, the Diagnostics segment is involved in the development and sale of diagnostic kits. Furthermore, through its RNA Interference division, Pharma Mar is advancing therapeutics designed to modulate or silence gene expression for therapeutic benefit. Established in 1986, the company maintains its headquarters in Madrid, Spain.
Sector: Biotechnology
Industry: Biotechnology
Pharma Mar, S.A.
- 0.2%
- 23.1K
- 240.21
Float 12.91M · FMP free float
The cost to borrow PHMMF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 100.0%
- No fails on record for 16–31 Oct 2026.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 23.1K sh |
| Oct 15, 2026 | 23.1K sh |
| Sep 30, 2026 | 23.3K sh |
| Sep 15, 2026 | 23.3K sh |
| Aug 31, 2026 | 8.7K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 9, 2026 | 100.0% |
| Nov 3, 2026 | 100.0% |
| Oct 26, 2026 | 100.0% |
| Oct 13, 2026 | 100.0% |
| Aug 31, 2026 | 100.0% |
130 calendar days requested; 6 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for PHMMF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 23,060 PHMMF shares were sold short (0.18% of a 12.91M-share float, 240.21 days to cover).